Agentix
AGENTIX Corp. is a clinical-stage biotechnology company focused on developing novel, science-driven biopharmaceuticals targeting the endocannabinoid system for the treatment of metabolic diseases such as Type 2 Diabetes Mellitus, Chronic Obesity, NAFLD, and NASH. The company aims to leverage proprietary technologies and strategic partnerships to advance its product pipeline and achieve market exclusivity in multiple therapeutic areas.
Industries
Nr. of Employees
small (1-50)
Agentix
Corporate Office: 32932 Pacific Coast Highway, #14-254 Dana Point, California 92629
Products
CB1 receptor antagonist (preclinical candidate)
A peripherally‑acting CB1 receptor antagonist candidate that has demonstrated preclinical activity to lower blood glucose, body weight and hepatic lipids in rodent models; intended for metabolic disease indications.
Cellular biocomplex delivery platform
A multi-component delivery platform composed of proteins, lipids and carbohydrates capable of encapsulating multiple bioactive substances and engineered for target tissue delivery and stability under varied conditions.
Partner consumer wellness and nutraceutical product lines
Select consumer-facing wellness and nutraceutical product brands associated with the company's investment and partnership activities.
CB1 receptor antagonist (preclinical candidate)
A peripherally‑acting CB1 receptor antagonist candidate that has demonstrated preclinical activity to lower blood glucose, body weight and hepatic lipids in rodent models; intended for metabolic disease indications.
Cellular biocomplex delivery platform
A multi-component delivery platform composed of proteins, lipids and carbohydrates capable of encapsulating multiple bioactive substances and engineered for target tissue delivery and stability under varied conditions.
Partner consumer wellness and nutraceutical product lines
Select consumer-facing wellness and nutraceutical product brands associated with the company's investment and partnership activities.
Services
Partnership-based R&D with academic and research institutions to support discovery, preclinical testing and candidate advancement.
Exclusive licensing and commercialization partnerships for synthetic small-molecule candidates and associated intellectual property.
Partnership-based R&D with academic and research institutions to support discovery, preclinical testing and candidate advancement.
Exclusive licensing and commercialization partnerships for synthetic small-molecule candidates and associated intellectual property.
Expertise Areas
- Endocannabinoid therapeutics (CB1/CB2)
- Clinical development and trial advancement
- Preclinical pharmacology and animal models
- Drug delivery and formulation
Key Technologies
- Endocannabinoid system targeting (CB1/CB2)
- Peripherally-restricted small-molecule design (tPSA modification)
- Cellular biocomplex delivery platform
- Liposome-based delivery